Results 81 to 90 of about 67,431 (260)

Unravelling the mechanisms of resistance to imatinib mesylate in chronic myeloid leukemia: a proteomic approach

open access: yes, 2010
Imatinib mesylate is a potent inhibitor of the Bcr-Abl tyrosine kinase, an oncoprotein that plays a key role in the development of chronic myeloid leukemia. Consequently, imatinib is used as front-line therapy for this disease.
Colavita, Irene
core  

Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results

open access: yes, 2010
Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with no known efficacious therapy. Imatinib is a tyrosine kinase inhibitor with potential efficacy to treat fibrotic lung disease.
Daniels, Craig E   +6 more
core   +1 more source

Small‐Molecule Kinase Inhibitors Modulating Circadian Rhythms

open access: yesMedicinal Research Reviews, EarlyView.
ABSTRACT The circadian clock mechanism generates 24‐h rhythms crucial for regulating various physiological processes, and its dysregulation has been implicated in numerous diseases. In cells, the circadian clock operates through a transcriptional‐translational feedback loop, where phosphorylation plays a pivotal role in maintaining accurate circadian ...
Irene Castellino   +3 more
wiley   +1 more source

β‐elemene promotes ferroptosis to improve the sensitivity of imatinib in gastrointestinal stromal tumours by targeting N6AMT1

open access: yesClinical and Translational Medicine
Background Imatinib has been widely used in gastrointestinal stromal tumours and significantly improved the prognosis of GIST patients, but approximately half of patients develop acquired treatment resistance, highlighting the urgency for novel ...
Jin Lan   +19 more
doaj   +1 more source

Disease–Drug–Drug Interaction of Imatinib in COVID‐19 ARDS: A Pooled Population Pharmacokinetic Analysis

open access: yesCPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 583-595, March 2025.
ABSTRACT Prior pharmacokinetic (PK) analysis revealed that increased alpha‐1‐acid glycoprotein (AAG) levels are associated with decreased imatinib unbound fraction in coronavirus disease 2019 (COVID‐19) patients. This study aimed to investigate the PK of total and unbound concentrations of imatinib and the metabolite N‐desmethyl imatinib in ...
Medhat M. Said   +10 more
wiley   +1 more source

Development and targeted use of nilotinib in chronic myeloid leukemia

open access: yesDrug Design, Development and Therapy, 2008
Carmen Fava, Hagop Kantarjian, Jorge Cortes, Elias JabbourDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USAAbstract: The development of imatinib has resulted in sustained hematologic and cytogenetic remissions
Carmen Fava   +3 more
doaj  

Imatinib and its combination with 2,5-dimethyl-celecoxibinduces apoptosis of human HT-29 colorectal cancer cells

open access: yesResearch in Pharmaceutical Sciences, 2017
Mono-targeting by imatinib as a main antitumor agent does not always accomplish complete cancer suppression. 2,5-dimethyl-celecoxib (DMC) is a close structural analog of the selective cyclooxygenase-2 (COX-2) inhibitor, celecoxib, that lacks COX-2 ...
Somayeh Atari-Hajipirloo   +3 more
doaj   +1 more source

Whole‐transcriptome sequencing analyses identified exosomal circular RNAs in the plasma of pancreatic cancer patients as novel blood‐based biomarkers of disease

open access: yesVIEW, EarlyView.
Pancreatic cancer (PaCa) has a poor prognosis, with low resection rates and high relapse rates, highlighting the urgent need for novel diagnostic biomarkers. Here, we performed whole‐transcriptome sequencing of plasma‐derived exosomes from PaCa patients and identified several differentially expressed circular RNAs (circRNAs).
Xiaomeng He   +10 more
wiley   +1 more source

Comparable efficacy and safety of generic and branded imatinib for patients with chronic myeloid leukemia in China

open access: yesTherapeutic Advances in Hematology
Background: Generics imatinib became an alternative treatment option for chronic myeloid leukemia (CML) patients in China. However, clinicians and patients alike harbor concerns regarding the long-term safety of generic imatinib.
Fang Cheng   +5 more
doaj   +1 more source

Staging concept for aging management: Definition, mechanism, and coping strategies

open access: yesVIEW, EarlyView.
We divided the overall aging stage into “pre‐aging”, “aging compensation”, and “aging disability”. For each stage, we delineate the clinical presentations, biological phenomena, theoretical underpinnings, and key management priorities. Abstract Aging, as a gradual and largely irreversible biological process, characterized by declining organismal ...
Zhonghan Wang   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy